A Phase 1 interventional study of Autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease, sponsored by Xuanwu Hospital, Beijing. Recruiting at 1 site in China. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Xuanwu Hospital, Beijing · Phase 1, Interventional, and Treatment
This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.
Parkinson's Disease (PD) is the second most common neurodegenerative disease, caused by progressive depletion of midbrain dopaminergic neurons in the substantia nigra pars compacta. This clinical study will include the preparation of dopaminergic neural precursor cells derived from neural stem cells through reprogramming of patient's peripheral blood mononuclear cells (PBMCs), and transplantation of the obtained cells into the brains of PD patients by stereotaxic injection. Safety, tolerability, evidence of cell survival (using PET scan), and the efficacy on PD symptoms will be assessed at different time points up to 12 months post-transplantation.
4,487 studies on the registry are indexed under Parkinson Disease; 1,081 are open to participants now.
This study's planned enrollment of 6 is below the median of 40 across 3,293 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Xuanwu Hospital, Beijing is the lead sponsor of 346 studies on the registry; 217 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Ages between 30 and 85 years, males or females; Diagnosed to be Parkinson's disease patients according to MDS Parkinson's disease diagnostic criteria; Disease history over 3 years; Hoehn and Yahr Stage less than or equal to 4 during the medication "on" time; Responsive to levodopa treatment (Maximum rate of improvement in MDS-UPDRS, part 3, is over 30%).
Exclusion Criteria:
Atypical Parkinsonian syndrome or secondary Parkinsonian syndrome; Accompanied with other central nervous system diseases; With other severe systemic diseases or dysfunction; With severe psychiatric disorders; Subjects are using hormone or cytotoxic drugs and cannot stop taking the drug during the trial; With cognitive disorders (MMSE\<24); With severe dyskinesia (MDS-UPDRS part 4, score in 4.1/4.2 ≥ 2); Subjects have undergone previous brain surgery; Subjects are long-term user of anticoagulant; Subjects have intracranial lesions which may affect the surgery or follow-up studies as assessed by imaging; Subjects are unable to undergo MRI or AV133 PET examination; Pregnancy or in preparation for pregnancy; Not suitable to participate in this clinical trial as assessed by the study investigators/physicians.
The patients will receive transplantation of autologous induced neural stem cell-derived DA precursor cells.
Drug: Autologous induced neural stem cell-derived DA precursor cells
The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.
Assessment of changes during the medication "off" time in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III, in comparison with baseline values.
Minimum score: 0; Maximum score: 132; Higher scores mean a worse outcome.
Time frame: Within 12 months post-transplantation
Incidence and severity of transplant-related adverse events.
Time frame: Within 12 months post-transplantation
Assessment of changes in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part I, in comparison with baseline values.
Minimum score: 0; Maximum score: 52; Higher scores mean a worse outcome.
Time frame: Within 12 months post-transplantation
Assessment of changes in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part II, in comparison with baseline values.
Minimum score: 0; Maximum score: 52; Higher scores mean a worse outcome.
Time frame: Within 12 months post-transplantation
Assessment of changes in Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part IV, in comparison with baseline values.
Minimum score: 0; Maximum score: 24; Higher scores mean a worse outcome.
Time frame: Within 12 months post-transplantation
Assessment of changes during the medication "off" time in motor function by using Purdue Pegboard test and gait analyzer, in comparison with baseline values.
Time frame: Within 12 months post-transplantation
Assessment of changes from baseline in total daily OFF time (or ratio of OFF time to daytime waking hours) at 12 months post-surgery.
Time frame: Within 12 months post-transplantation
Assessment of changes in Unified Dyskinesia Rating Scale in comparison with baseline values.
Minimum score: 0; Maximum score: 104; Higher scores mean a worse outcome.
Time frame: Within 12 months post-transplantation
Assessment of changes in daily levodopa-equivalent dose in comparison with baseline values.
Time frame: Within 12 months post-transplantation
Assessment of changes in Parkinson's Disease Questionnaire (PDQ-39) in comparison with baseline values.
Time frame: Within 12 months post-transplantation
Assessment of changes in AV133 PET imaging in comparison with baseline values.
Time frame: Within 12 months post-transplantation
Assessment of changes in International Parkinson and Movement Disorder Society - Non-Motor Rating Scale (NMSS), in comparison with baseline values.
Minimum score: 0; Maximum score: 960; Higher scores mean a worse outcome.
Time frame: Within 12 months post-transplantation
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xuanwu Hospital, Beijing